News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Boston Life Sciences Announces Expansion of Clinical Program in ADHD Diagnosis (Business Wire) ... physiologic/biochemical abnormality (increased numbers of DATs) in certain regions of the brain, and that this abnormality could be detected and measured using Altropane as an objective test....... a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders;... - Aug 20 2:10 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010820/202470.html

Posted on: 08/20/2001

"Yahoo - Boston Life Sciences Announces Expansion of Clinical Program in ADHD Diagnosis"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
BLSI
2.7
+0.1
delayed 20 mins - disclaimer

Monday August 20, 2:10 pm Eastern Time

Press Release

SOURCE: Boston Life Sciences, Inc.

Boston Life Sciences Announces Expansion of Clinical Program in ADHD Diagnosis

Lead Front Page Article in New York Times Highlights Need for Objective Diagnosis

Company plans to initiate Phase II study using Altropane(TM) to diagnose ADHD in children

BOSTON--(BW HealthWire)--Aug. 20, 2001-- Boston Life Sciences (NASDAQ: BLSI - news) announced that the Company has expanded its clinical program using Altropane as an ADHD diagnostic agent to include a Phase II study in children. The decision to initiate a Phase II diagnostic study in children was based on the highly successful Altropane Phase II study in adults with ADHD, and prior agreed-upon guidelines with the FDA. The design of the study calls for the enrollment of 80 subjects, ages 8-17, in two of the country's premier pediatric hospitals. The principal investigators are considered among the world's experts in diagnosing and treating ADHD in children. The study is designed to verify the findings previously found in adults, that children with expertly-diagnosed ADHD have elevated numbers of dopamine transporters (DATs) compared to an age-matched control group.

"The need for an objective diagnosis of ADHD in children has never been more urgent," stated Marc Lanser, MD, Chief Scientific Officer of BLSI. "Yesterday's (8/19/01) lead article in the New York Times entitled 'Schools' Backing of Behavior Drugs Comes Under Fire,' reported on the effort by state legislatures to prevent schools from recommending or requiring that parents put children on medication, the direct-to-parent marketing efforts by some pharmaceutical companies, as well as the ongoing controversy surrounding the diagnosis of ADHD and the lack of an objective test for the disorder. Our collaborating scientists were the first to demonstrate that ADHD subjects do have a particular physiologic/biochemical abnormality (increased numbers of DATs) in certain regions of the brain, and that this abnormality could be detected and measured using Altropane as an objective test. The results of our successful Phase II study have been submitted for publication and will be presented at the upcoming meeting of the European Society of Nuclear Medicine in Naples, Italy. We look forward to demonstrating the ability of Altropane to detect this abnormality in children, as we have in adults. We believe that Altropane has the potential to significantly contribute to the resolution of the diagnostic and treatment controversies associated with ADHD in both adults and children," added Dr. Lanser.

Altropane is being developed by BLSI for the objective diagnosis of early Parkinson's Disease (PD) and ADHD. The clinical development program for the diagnosis of PD has been completed (including a successful Phase III study), and the Company hopes to file a New Drug Application for the PD indication later this year. The clinical development schedule for the ADHD indication calls for the completion of the ADHD clinical program (including Phase III) late in 2002, with the filing for approval for the ADHD indication as soon as possible thereafter.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane and Fluoratec, radioimaging agents for the diagnosis of PD and ADHD; Troponin, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact may represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.


Contact:
     Investors
     Joseph Hernon
     Boston Life Sciences, Inc.
     617.425.0200, ext.18
     IR@bostonlifesciences.com
        or
     Corporate
     Marc Lanser
     Boston Life Sciences, Inc.
     617.425.0200, ext. 13
     mlanser@bostonlifesciences.com
        or
     Media
     Lynn Blenkhorn
     Noonan/Russo Communications
     212.696.4455, ext. 241
     l.blenkhorn@noonanrusso.com

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Boston Life Sciences Inc (NasdaqNM:BLSI - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740